Wichterman Troy 4
4 · BIOLIFE SOLUTIONS INC · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
BioLife (BLFS) CFO Troy Wichterman Receives Awards, Withholds Shares
What Happened
Troy Wichterman, Chief Financial Officer of BioLife Solutions (BLFS), was granted two restricted stock awards on 2026-02-24 totaling 96,016 shares (31,150 and 64,866). On the same date, 25,525 shares were disposed of (withheld) to satisfy tax withholding obligations at an indicated per-share value of $22.65, totaling $578,141. The grants were reported as awards (code A) and the withholding as tax withholding (code F).
Key Details
- Transaction date: 2026-02-24; Form 4 filed 2026-02-26 (appears timely).
- Grants: 31,150 and 64,866 restricted shares (grant price N/A for restricted stock awards).
- Withholding: 25,525 shares withheld at $22.65 per share for taxes; total value reported $578,141.
- Footnotes:
- F1: One award is part of the 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary, then quarterly over 12 quarters (part of 2026 compensation).
- F2: The market-based award vested at ~156% of the originally granted amount based on total shareholder return vs. peer group for 2024–2025.
- F3: The 25,525 shares represent shares withheld to cover tax withholding obligations upon vesting.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Type of activity: awards/grants (acquisitions) with shares withheld for taxes — not an open-market sale.
Context
- The awards are compensation-related restricted stock that vested (in part based on performance metrics). The withheld shares were surrendered to cover tax liabilities on those vesting events; this is a routine administrative action and not necessarily a signal of bearish insider selling.
- Market-based vesting that paid out at ~156% indicates performance metrics exceeded targets for the relevant period, resulting in a larger-than-granted payout.
Insider Transaction Report
Form 4
Wichterman Troy
Chief Financial Officer
Transactions
- Award
Common Stock
[F1]2026-02-24+31,150→ 181,896 total - Award
Common Stock
[F2]2026-02-24+64,866→ 246,762 total - Tax Payment
Common Stock
[F3]2026-02-24$22.65/sh−25,525$578,141→ 221,237 total
Footnotes (3)
- [F1]The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.
- [F2]The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- [F3]Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Signature
/s/ Troy Wichterman|2026-02-26